Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 15/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13352182 | 1.00 | KLKB1 (0.52) | KLKB1CAPN1GAARAB9ACTSS | |
| SCHEMBL2842957 | 0.86 | PRKCI (0.55) | CAPN1CTSSPRKCI | |
| SCHEMBL14305627 | 0.86 | PRKCI (0.55) | CAPN1CTSSPRKCI | |
| SCHEMBL7956796 | 0.81 | EGLN1 (0.57) | CAPN1GAARAB9A | |
| SCHEMBL7956801 | 0.81 | EGLN1 (0.57) | CAPN1GAARAB9A | |
| SCHEMBL7650844 | 0.78 | ITGB1 (0.50) | KLKB1CAPN1GAARAB9ATP53 | |
| SCHEMBL5211521 | 0.78 | GAA (0.51) | CAPN1GAARAB9ATP53 | |
| SCHEMBL3927028 | 0.78 | CTSL (0.71) | GAARAB9ACTSSTP53 | |
| SCHEMBL28790851 | 0.78 | CTSL (0.71) | GAARAB9ACTSSTP53 | |
| SCHEMBL7962262 | 0.77 | PSMB5 (0.54) | GAARAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | KLKB1 3538/4885CAPN1 422/4885GAA 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.